Table 2. Drugs and drug combinations used in different lines of treatment.
| 1st line | 2nd line | 3rd line therapy | |||||
|---|---|---|---|---|---|---|---|
| Chemotherapy + ICI (N=77) | N (%) | R+D (N=77) | N (%) | (N=20) | N (%) | ||
| Platinum + pemetrexed + pembrolizumab | 50 (64.9) | ||||||
| Platinum + paclitaxel/nab-paclitaxel + pembrolizumab | 9 (11.7) | Docetaxel + ramucirumab | 77 [100] | Chemotherapy mono | 8 [40] | ||
| Platinum + paclitaxel/nab-paclitaxel + atezolizumab | 8 (10.4) | Chemotherapy combination | 3 [15] | ||||
| Platinum + gemcitabine/vinorelbine + durvalumab + tremelimumab | 3 (3.9) | ICI | 6 [30] | ||||
| Platinum + pemetrexed + durvalumab +tremelimumab | 2 (2.6) | TKI | 3 [15] | ||||
| Carboplatin + paclitaxel + bevacizumab + atezolizumab | 2 (2.6) | ||||||
| Platinum + gemcitabine/vinorelbine + pembrolizumab | 2 (2.6) | ||||||
| Platinum + gemcitabine/vinorelbine + pembrolizumab | 1 (1.3) | ||||||
ICI, immune-checkpoint-inhibitor; TKI, tyrosine kinase inhibitor.